Shares of VWR Corp (NASDAQ:VWR) ended Thursday session in red amid volatile trading. The shares closed down -1.14 points or -3.98% at $27.47 with 2.69 million shares getting traded. Post opening the session at $27.37, the shares hit an intraday low of $26.97 and an intraday high of $27.65 and the price vacillated in this range throughout the day. The company has a market cap of $3.65 billion and the numbers of outstanding shares have been calculated to be 131.48 million shares.
VWR Corp (VWR) on May 19, 2016 announced that James Kalinovich, Treasurer, and John Sweeney, VP of Investor Relations, will present at the UBS Global Healthcare Conference to be held in New York City on May 24, 2016 at 4:00 PM ET.
A webcast of the presentation will be available on the Investor Relations section of the Company`s website at www.vwr.com. An online replay will be available immediately following the presentation and will be available for the following 90 days.
Shares of Amgen, Inc. (NASDAQ:AMGN) ended Thursday session in red amid volatile trading. The shares closed down -2.16 points or -1.43% at $148.67 with 3.02 million shares getting traded. Post opening the session at $149.45, the shares hit an intraday low of $147.12 and an intraday high of $150.23 and the price vacillated in this range throughout the day. The company has a market cap of $112.22 billion and the numbers of outstanding shares have been calculated to be 751.22 million shares.
Amgen, Inc. (AMGN) on May 19, 2016 announced voting results from the Company’s Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, François de Carbonnel, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Judith C. Pelham, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen’s Board of Directors. Each director received approximately 96 percent or more of the votes cast “For.” Also at the meeting, retiring director Vance D. Coffman was recognized for his contributions while on the Board. With the re-election of all of the director nominees and Dr. Coffman’s retirement, Amgen currently has 13 directors.
With approximately 98 percent of the votes cast “For,” stockholders ratified Ernst & Young LLP as Amgen’s independent registered public accountants for the year ending Dec. 31, 2016.
Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, commonly known as “Say on Pay.” The non-binding proposal gives stockholders the opportunity to endorse or not endorse Amgen’s executive pay programs and policies. Say on Pay received approximately 97 percent of the votes cast “For” the proposal.
The stockholder proposal to change the voting standard applicable to non-binding proposals submitted by stockholders did not pass, receiving approximately 7 percent of the votes cast “For” the proposal.
Shares of Opko Health Inc. (NYSE:OPK) ended Thursday session in red amid volatile trading. The shares closed down -0.19 points or -1.90% at $9.81 with 2.65 million shares getting traded. Post opening the session at $9.88, the shares hit an intraday low of $9.76 and an intraday high of $10.03 and the price vacillated in this range throughout the day. The company has a market cap of $5.39 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on May 11, 2016 announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE®.
Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO, Dr. Laidlaw served as Relypsa’s Executive Director, Medical Affairs, and Sanofi’s National Director, Medical Science Liaisons, Medical Affairs.
“Doug is a key addition to the management team in OPKO’s Renal Division,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. “A well-conceived and executed medical education strategy is critical to Rayaldee’s acceptance by U.S. healthcare professionals.”